Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Non-Current Deffered Revenue (2016 - 2018)

Neurocrine Biosciences filings provide 9 years of Non-Current Deffered Revenue readings, the most recent being $18.1 million for Q4 2018.

  • On a quarterly basis, Non-Current Deffered Revenue rose 477.8% to $18.1 million in Q4 2018 year-over-year; TTM through Dec 2018 was $18.1 million, a 477.8% increase, with the full-year FY2018 number at $18.1 million, up 477.8% from a year prior.
  • Non-Current Deffered Revenue hit $18.1 million in Q4 2018 for Neurocrine Biosciences, up from $12.1 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $18.1 million in Q4 2018 to a low of $1.5 million in Q4 2016.
  • Median Non-Current Deffered Revenue over the past 5 years was $10.2 million (2015), compared with a mean of $6.8 million.
  • The widest YoY moves for Non-Current Deffered Revenue: up 543.46% in 2017, down 83.45% in 2017.
  • Neurocrine Biosciences' Non-Current Deffered Revenue stood at $1.9 million in 2014, then decreased by 10.7% to $1.7 million in 2015, then decreased by 14.55% to $1.5 million in 2016, then surged by 114.43% to $3.1 million in 2017, then skyrocketed by 477.8% to $18.1 million in 2018.
  • The last three reported values for Non-Current Deffered Revenue were $18.1 million (Q4 2018), $12.1 million (Q3 2018), and $10.2 million (Q2 2018) per Business Quant data.